We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+48.43%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$1.2B
AUM Growth
+$407M
Cap. Flow
-$12.9M
Cap. Flow %
-1.07%
Top 10 Hldgs %
99.85%
Holding
14
New
1
Increased
3
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$75.6M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$27.4M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$2.25M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$806K

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$104M
2
PBYI icon
Puma Biotechnology
PBYI
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 64.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDCO
1
DELISTED
Medicines Co
MDCO
$357M 29.63%
4,202,000
– –
BIIB icon
2
Biogen
BIIB
$30B
$191M 15.84%
643,000
– –
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$696M
$137M 11.39%
10,307,000
+204,000
+2% +$2.25M
ICPT
4
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$107M 8.85%
860,000
+9,000
+1% +$806K
AGN
5
DELISTED
Allergan plc
AGN
$89.4M 7.42%
467,500
-575,000
-55% -$104M
INVA icon
6
Innoviva
INVA
$1.55B
$88.4M 7.34%
6,242,000
– –
ALKS icon
7
Alkermes
ALKS
$8.22B
$77.6M 6.44%
+3,805,000
New +$75.6M
JAZZ icon
8
Jazz Pharmaceuticals
JAZZ
$15.9B
$66.2M 5.5%
443,500
+201,500
+83% +$27.4M
MRSN
9
DELISTED
Mersana Therapeutics
MRSN
$21.5M 1.78%
150,000
– –
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
$1.65M 0.14%
185,185
– –
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$128K 0.01%
1,000
– –
ABBV icon
12
AbbVie
ABBV
$443B
$88K 0.01%
1,000
– –
PBYI icon
13
Puma Biotechnology
PBYI
$404M
– –
-1,417,000
Closed -$15.3M

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Sarissa Capital Management held 14 positions worth $1.2B, up 51% from $798M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management's Q4 2019 filing shows 1 new, 3 increased, 1 reduced and 1 closed positions. Its largest new stake was Alkermes: 3,805,000 shares worth $77.6M. The largest sale was Allergan plc, an estimated $104M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 74% a quarter earlier.

  • Sarissa Capital Management's largest Q4 2019 buy was Alkermes: 3,805,000 shares worth $77.6M.
  • Sarissa Capital Management added most to Jazz Pharmaceuticals in Q4 2019, an estimated $27.4M increase.
  • Sarissa Capital Management's biggest Q4 2019 reduction was Allergan plc, cutting an estimated $104M.
  • Sarissa Capital Management fully exited Puma Biotechnology in Q4 2019, selling an estimated $15.3M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $1.2B portfolio in Q4 2019.
  • Sarissa Capital Management opened 1 new position and closed 1 in Q4 2019.
  • Sarissa Capital Management's portfolio value rose 51% quarter-over-quarter to $1.2B.

Based on Sarissa Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.